SIP
LXRX icon

Stoneridge Investment Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Stoneridge Investment Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,038
Closed -$494K – 232
2017
Q4 		$494K Buy
+50,038
New +$520K 0.08% 119
2016
Q2 		– Sell
-43,948
Closed -$525K – 308
2016
Q1 		$525K Sell
43,948
-180,502
-80% -$1.89M 0.08% 203
2015
Q4 		$2.99M Buy
+224,450
New +$2.76M 0.4% 79
2015
Q2 		– Sell
-5,696
Closed -$38K – 292
2015
Q1 		$38K Buy
+5,696
New +$38.9K ﹤0.01% 264

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Stoneridge Investment Partners's LXRX Position: Q1 2018 in Review

Stoneridge Investment Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2018, closing a stake of 50,038 shares — an estimated $494K sold.

Stoneridge Investment Partners first reported a position in LXRX in Q1 2015 and held it in 4 quarters. The position peaked at $2.99M in Q4 2015. 126 funds tracked by Wall St. Rank hold LXRX as of Q1 2018.

  • Stoneridge Investment Partners reported no remaining Lexicon Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Stoneridge Investment Partners sold 50,038 Lexicon Pharmaceuticals shares in Q1 2018, an estimated $494K.
  • Stoneridge Investment Partners first reported a position in Lexicon Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Stoneridge Investment Partners's Lexicon Pharmaceuticals position peaked at $2.99M in Q4 2015.
  • 126 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2018.

Based on Stoneridge Investment Partners's 13F filing for Q1 2018, filed 27 Apr 2018.